For instance, the recommendation for a medulloblastoma patient with an activating PIK3CA mutation responding well to standard chemotherapy and radiation would be to continue SOC rather than receive a new, specific targeted therapy. This evidence concerns the gene PIK3CA and medulloblastoma.